{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Missing Baseline ECOG Score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Baseline ECOG Score = 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]}],"title":"Baseline ECOG Score = 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}],"title":"Baseline ECOG Score = 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline ECOG Score = 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline ECOG Score = 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"description":"The ECOG scale is as follows: Grade 0: Fully active, able to perform all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory, able to carry out light work; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or chair. Data reported is the shift from Baseline ECOG score to best on-study assessment score.","groups":[{"description":"Participants with a missing best on study ECOG performance score, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG000","title":"Missing"},{"description":"Participants with a best on study ECOG performance score of 0, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG001","title":"Best ECOG = 0"},{"description":"Participants with a best on study ECOG performance score of 1, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG002","title":"Best ECOG = 1"},{"description":"Participants with a best on study ECOG performance score of 2, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG003","title":"Best ECOG = 2"},{"description":"Participants with a best on study ECOG performance score of 3, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG004","title":"Best ECOG = 3"},{"description":"Participants with a best on study ECOG performance score of 4, who received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG005","title":"Best ECOG = 4"}],"paramType":"NUMBER","populationDescription":"Safety Population: all participants who received at least 1 dose of romidepsin.","reportingStatus":"POSTED","timeFrame":"From Baseline up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.","title":"Change in Eastern Cooperative Oncology Group (ECOG) Performance Status","type":"SECONDARY","unitOfMeasure":"participants"}